Introduction
Close to 13% of the adult world population suffers from some form of chronic kidney disease (CKD) (1) . The high social, economic, and mortality burden of CKD highlights the urgent need for a better understanding of its pathophysiology in the search for new and effective therapies (2) . Approximately 90% of kidney diseases leading to CKD originate in the kidney filters (glomeruli) (3) . For this reason, glomerular resident cells are important targets of current research.
The cellular origins of glomerulosclerosis involve activation of parietal epithelial cells (PECs) and progressive podocyte depletion. While mammalian target of rapamycin-mediated (mTORmediated) podocyte hypertrophy is recognized as an important signaling pathway in the context of glomerular disease, the role of podocyte hypertrophy as a compensatory mechanism preventing PEC activation and glomerulosclerosis remains poorly understood. In this study, we show that glomerular mTOR and PEC activation-related genes were both upregulated and intercorrelated in biopsies from patients with focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy, suggesting both compensatory and pathological roles. Advanced morphometric analyses in murine and human tissues identified podocyte hypertrophy as a compensatory mechanism aiming to regulate glomerular functional integrity in response to somatic growth, podocyte depletion, and even glomerulosclerosis -all of this in the absence of detectable podocyte regeneration. In mice, pharmacological inhibition of mTOR signaling during acute podocyte loss impaired hypertrophy of remaining podocytes, resulting in unexpected albuminuria, PEC activation, and glomerulosclerosis. Exacerbated and persistent podocyte hypertrophy enabled a vicious cycle of podocyte loss and PEC activation, suggesting a limit to its beneficial effects. In summary, our data highlight a critical protective role of mTOR-mediated podocyte hypertrophy following podocyte loss in order to preserve glomerular integrity, preventing PEC activation and glomerulosclerosis.
Podocytes are glomerular epithelial cells that cover the filtration surface area and serve as master regulators of kidney function (4) . As terminally differentiated cells, podocytes cannot reenter the cell cycle to complete cytokinesis, limiting their capacity for self-renewal (5) . Wharram et al. (6) showed that podocyte loss is sufficient to cause glomerulosclerosis, leading to progressive loss of kidney function and, thereby, CKD. Importantly, humans lose podocytes during normal aging (7) and exhibit more extensive podocyte loss in association with the leading causes of CKD, including diabetes (8, 9) . Therefore, podocyte depletion is considered a unifying principle of glomerular disease (3) .
Glomerulosclerosis develops after podocyte depletion has reached a critical threshold that is still inaccurately defined (approximately 20%-40% podocyte loss) (6, 10, 11) . Recent evidence shows that parietal epithelial cells (PECs), glomerular resident cells that are part of Bowman's capsule, play key roles in the development of glomerulosclerotic lesions. PECs can become activated in a process defined by increased potential for migration to the glomerular tuft, prominent proliferation, abnormal production of extracellular matrix, and de novo expression of the cell surface marker CD44 (12) (13) (14) . However, the interaction between podocyte depletion and PEC activation remains poorly understood.
When podocyte depletion does not reach the critical threshold for disease, transient acute albuminuria is followed by clinical recovery without overt permanent structural changes (6, 11) , suggesting that low levels of podocyte loss trigger an adaptive response in remaining podocytes that is able to preserve glomerular integrity. It has been hypothesized that remaining podocytes undergo hypertrophy in order to recover the filtration surface area, at least until the degree of stress is no longer tolerable (15) . However, the lack of reliable methods for the accurate and precise analysis of podocyte number and size has limited the study of podocyte hypertrophy as an adaptive response in vivo.
The mammalian target of rapamycin complex 1 (mTORC1) signaling pathway, a key regulator of cell growth, is essential for normal nephrogenesis (16) (17) (18) . In contrast, hyperactivity of mTOR signaling in podocytes plays a central role in the development of diabetic nephropathy (19) and crescentic nephritis (20) . mTOR inhibition has proven to be an effective therapeutic approach in animal models of glomerular disease and in small clinical studies (16) , but it has also been associated with development and exacerbation of proteinuria and glomerulosclerosis (21) (22) (23) (24) (25) (26) (27) . Recent studies by Zschiedrich, et al. (28) , and Nishizono, et al. (29) , have shown that ablation/inhibition of mTORC1 in podocytes resulted in an increased vulnerability toward glomerulosclerosis in both mice and rats, raising questions about the role of mTORC1 signaling as an important adaptive mechanism in podocytes.
Our current study shows that mTOR-mediated podocyte hypertrophy is required to sustain glomerular integrity following podocyte loss, suggesting that podocyte hypertrophy prevents the development of PEC activation and glomerulosclerosis in the absence of podocyte regeneration. Importantly, our findings also indicate that exacerbated mTOR-mediated podocyte hypertrophy is connected to a vicious cycle of progressive podocyte loss that also results in PEC activation and glomerulosclerosis. Thus, podocyte hypertrophy provides a classical example of a compensatory response that can become maladaptive with time and persistent damage.
Results
Upregulation of mTOR and PEC activation-related genes in human FSGS. Glomerular extracts from biopsies in patients with primary focal segmental glomerulosclerosis (FSGS) showed an upregulation of genes underlying mTOR signaling in comparison with living donors with mTORC1 signaling being upregulated in podocytes, as shown by phosphorylation of ribosomal protein S6 (p-rp-S6), a downstream target of mTORC1 directly associated with cell size regulation ( Figure 1A ). Glomerular extracts from biopsies in patients with primary FSGS showed an upregulation of PEC activation-related genes in comparison with living donors with PEC activation marker CD44, a cell surface glycoprotein that is expressed de novo by activated PECs, being identified in serial sections where histological identification of a segmental lesion based on periodic acid-Schiff (PAS) and expression of CD44 in the same area were confirmed ( Figure 1B ). While all markers of PEC activation were associated with at least 1 mTOR-related gene, the best correlations were found using CD9, CD44, CXCR4, and KRT19 ( Figure 1C ). These associations suggest that PEC activation and podocyte hypertrophy may have direct interactions in the development of human FSGS.
Human podocyte hypertrophy during somatic growth and FSGS. First, we aimed to quantify the degree of podocyte depletion and hypertrophy in humans (Supplemental Tables 1-3 contain demographic data from included subjects; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.99271DS1). A combination of indirect immunofluorescence, confocal microscopy, and model-based stereology was applied in advanced podocyte morphometrical analyses (podometrics), including glomerular size, podocyte number, podocyte density, and ratios marking podocyte size (total podocyte volume per podocyte number, TPV:PN; and total podocyte volume per podocyte density, TPV:PD) in autopsied kidneys from children, nephrectomy samples from adults without kidney disease, and human biopsies from adult patients with FSGS.
While there was no statistical reduction in the number of podocytes between children and adults, there was a strong decrease in podocyte density (P < 0.0001). Podocyte number and density were significantly reduced in adult patients with primary FSGS compared with adult controls (P < 0.0001; Figure 1D ). There was a strong correlation between podocyte number and glomerular size in all 3 groups ( Figure 1E ). While the slopes were significantly different between children and adults (P < 0.0001), the slopes between adults and FSGS patients were identical, but the elevations were significantly different (P < 0.0001). Podocyte size showed graded increases from childhood to adulthood and then to adults with primary FSGS (P < 0.001; Figure 1F ). Together, the data suggest postnatal podocyte loss and hypertrophy across the full spectrum of glomerular sizes in the adult kidney, a process that is exacerbated in the context of FSGS.
Interestingly, podocyte densities and sizes from adults without kidney disease and patients with FSGS showed significant overlap (Supplemental Figure 1, A and B ). Furthermore, the percentage of glomeruli from FSGS patients was higher in the top quintiles of podocyte density (Q1 with the lowest values for podocyte density; Supplemental Figure 1C ) and size (Q5 with the highest values of TPV:PD; Supplemental Figure 1D ), reinforcing the concept that podocyte depletion and hypertrophy are closely associated. Mouse podocyte hypertrophy during somatic growth and FSGS. Given that human samples do not allow the study of dynamic cellular changes, we utilized a mouse model of selective podocyte depletion based on the expression of a mutated human diphtheria toxin (DT) receptor under a podocyte-specific promoter (Pod Cre iDTR). Noninjected mice showed a similar response to somatic growth as humans -as body size increased (Supplemental Figure 2A ), compensatory glomerular hypertrophy (Supplemental Figure 2B ) led to reductions in podocyte density (Supplemental Figure 2C ), which resulted in elevations in podocyte size (Supplemental Figure 2D) , confirming a similar response in mice and humans.
Pod Cre iDTR were injected either a low dose (50 ng/kg) or a high dose (100 ng/kg) of DT. Mice were continuously monitored via urinary albumin to creatinine ratios (UACRs) every 2 days. Experimental mice were sacrificed 1 week after DT injection, and tissue was collected for cellular analyses (Figure 2A ). While we observed a graded increase in albuminuria based on DT dose, the peak of albuminuria was identified around the same time point (day 6 after DT) in both groups ( Figure 2B) .
A representative 3-dimensional (3-D) reconstruction of an intact mouse glomerulus is provided as an example of our approach for advanced podometrics, which combines indirect immunofluorescence, solvent-based optical clearing, laser confocal microscopy, and 3-D bioinformatics ( Figure 2C ). Our results mirrored our findings in humans, as podocyte loss directly correlated with increases in podocyte size ( Figure 2 , D-G). As in humans, we observed a strong upregulation of mTORC1 in podocytes after acute podocyte loss ( Figure 2H ).
Quintile analysis of podocyte size confirmed the strong association between podocyte loss and hypertrophy, and it showed that even the highest quintile of podocyte size (Q5) contained glomeruli from control mice ( Figure 2I ), highlighting the concept of physiological mTOR-mediated podocyte hypertrophy.
In the second part of this experiment, DT-injected Pod Cre iDTR mice were monitored for 5 weeks ( Figure  3A ). By the end of the follow-up period, albuminuria resolved in mice injected with a low dose of DT and persisted in mice injected with a high dose of DT ( Figure 3B ). Furthermore, glomerulosclerotic lesions ( Figure  3C ) and activated PECs ( Figure 3D ) were only observed in mice injected with a high dose of DT. Interestingly, podocyte loss ( Figure 3E ) and hypertrophy ( Figure 3F ) remained after 5 weeks of DT injection at both doses.
Glomerular functional recovery: podocyte hypertrophy versus podocyte regeneration. While albuminuria was completely reversed in Pod Cre iDTR mice injected with a low dose of DT, Pod Cre iDTR mice injected with a high dose of DT showed only partial resolution of albuminuria 5 weeks after DT injection (Supplemental Figure 3A ). Podocyte hypertrophy was sustained between weeks 1 and 5 after DT injection at both doses (Supplemental Figure 3B) . Surprisingly, podocyte number appeared to increase by 11% (P < 0.0001) between weeks 1 and 5 only in mice injected with a high dose of DT (Supplemental Figure 3C ) -a finding that caught our attention, as it may suggest the possibility of podocyte regeneration. At week 1 after highdose DT injection, we could clearly identify podocytes with very negligible p57 nuclear expression (Supplemental Figure 3D ). We quantified the percentage of synaptopodin-positive (SNP + ) podocytes that coexpressed p57 in all groups (Supplemental Figure 3E ), which revealed that, even at baseline, approximately 1.52% of podocytes had low or negligible levels of p57 expression. While a low dose of DT barely altered this percentage (2.14%-2.20%), a high dose of DT led to a significant increase in p57podocytes at week 1 after DT injection (13.73%) that returned to normal (2.40%) by 5 weeks after DT injection, suggesting that the apparent increase in podocyte number most likely reflects reversible podocyte injury, where injured podocytes transiently downregulate expression of p57, which then returned to normal.
To further explore the possibility of podocyte regeneration in this model, we used a second transgenic mouse model for selective dose-dependent podocyte loss (Pod-rtTA-mT/mG-iDTR), which was based on a previous publication (30) . Upon doxycycline administration, podocytes permanently expressed eGFP and a mutated DT receptor, whereas all other cells were labeled with TdTomato ( Figure 4A) (10) . After a wash out period, DT was injected at multiple doses (see Methods). Mice were stratified into 2 categories based on histopathology analysis into DT with and without glomerulosclerotic lesions ( Figure 4B ). This definition also correlated with the presence of activated PECs ( Figure 4C ) and albuminuria ( Figure 4D ). As expected, we observed graded podocyte loss and hypertrophy, which mirrored our previous experiments ( Figure  4E ). Glomeruli from 1 kidney of each mouse were enzymatically digested into a single cell suspension and immunolabeled with a podocyte-specific antibody (podocin). Podocin + podocytes were isolated using flow cytometry and divided into eGFP + (genetically labeled podocytes) and TdTomato + (fraction of nonlabeled podocytes; Figure 4F ), which allowed the calculation of a percentage of eGFP + podocytes per mouse. Podocytes cannot reenter the cell cycle to undergo division (5) , which means that the percentage of eGFP + podocytes cannot expand due to podocyte mitosis. If podocyte regeneration were actively taking place, we would expect an expansion of the percentage of TdTomato + podocytes, which would directly reduce the percentage of eGFP + podocytes. However, we did not observe any changes in the percentage of eGFP + podocytes in any of the groups (Figure 4G ), and numbers of podocytes per glomerular cross-section had a strong inverse correlation with glomerulosclerosis ( Figure 4H ). Together, these findings provide strong evidence that sustained podocyte hypertrophy plays a central role in functional glomerular recovery in the absence of detectable podocyte regeneration.
Podocyte hypertrophy in diabetic mice and humans. Next, we focused on a mouse model that combines podocyte loss and glomerular hypertrophy. We induced diabetes in Pod Cre iDTR mice via 5 consecutive injections of streptozotocin (STZ; Supplemental Figure 4A ). Two weeks after the first STZ injection, plasma blood glucose was significantly elevated (Supplemental Figure 4B ). After 4 weeks of persistent hyperglycemia, STZ-injected mice developed mild albuminuria (Supplemental Figure 4C ). Six weeks after the first STZ injection, mice developed glomerular hypertrophy (Supplemental Figure 4D) , reductions in podocyte number and density (Supplemental Figure 4 , E and F), and increases in podocyte size (Supplemental Figure 4G) .
Human diabetic nephropathy shared a similar transcriptional profile as FSGS. Glomerular extracts from biopsies in patients with diabetic nephropathy showed an upregulation of mTOR signaling and PEC activation-related genes in comparison with living donors ( Figure 5, A and B) . P-rp-S6 was identified in podocytes ( Figure 5A ), and PEC activation marker CD44 was detected in scattered PECs ( Figure 5B ). While all markers of PEC activation were associated with at least 1 mTOR-related gene, the best correlations were found for KRT19 and CD44 ( Figure 5C ).
Next, we induced diabetes in Pod Cre iDTR mice via 5 consecutive injections of STZ, and after a period of 2 weeks to verify hyperglycemia, we injected low-dose DT ( Figure 5D ). Diabetic mice achieved the same level of hyperglycemia in both groups (DT-injected vs. vehicle-injected controls; Figure 5E ). Diabetes led to significant increases in kidney weight ( Figure 5F ), a surrogate marker of renal hyperfiltration. However, only diabetic mice injected with low-dose DT developed glomerulosclerotic lesions ( Figure 5G ) and PEC activation ( Figure 5H ) within 4 weeks after DT injection, despite losing the same number of podocytes as nondiabetic mice injected with a low dose of DT ( Figure 5I ). As in human biopsies, mTORC1 signaling was also upregulated in podocytes from diabetic mice injected with DT ( Figure 5J ). Reductions in podocyte density were comparable with those observed in mice injected with a high dose of DT ( Figure 5K ), as glomerular hypertrophy in diabetic mice acted as a second stressor. The exacerbated level of podocyte hypertrophy driven by podocyte loss and glomerular hypertrophy was comparable with FSGS induced by a high dose of DT ( Figure 5L ) and was not sufficient to prevent PEC activation or glomerulosclerosis. Together, these findings suggest that the degree of podocyte depletion marks the limits of compensatory podocyte hypertrophy and, thereby, preservation of glomerular integrity.
Exacerbated mTOR hyperactivation in mouse podocytes leads to PEC activation and FSGS. Tuberous sclerosis complex 1 (TSC1) is a well-known repressor of mTORC1 signaling, with its genetic deletion leading to a direct and persistent hyperactivation of mTORC1 (19) . In this experiment, we analyzed tissue collected between weeks 4 and 16 of age from Pod-TSC1 -/mice, where mTORC1 hyperactivation was confirmed in isolated podocytes ( Figure 6A ). Representative confocal images show clear increases in podocyte size and de novo PEC activation in Pod-TSC1 -/mice, where CD44 + PECs were observed in 50% of Pod-TSC1 -/mice by 4-6 weeks of age and 100% of Pod-TSC1 -/mice by 12-16 weeks of age ( Figure 6B ). Four-to 6-week-old Pod-TSC1 -/mice showing PEC activation had lower numbers of podocytes (Supplemental Figure 5A ) and higher glomerular volumes (Supplemental Figure 5B) than Pod-TSC1 -/mice without PEC activation, suggesting that accelerated podocyte loss in the context of exacerbated glomerular hypertrophy play central roles in the development of PEC activation.
Between 4 and 16 weeks of age, Pod-TSC1 -/mice showed progressive glomerular hypertrophy ( Figure  6C ) and podocyte loss ( Figure 6D ), leading to significant reductions in podocyte density ( Figure 6E ) and progressively exacerbated podocyte hypertrophy ( Figure 6F ). Importantly, podocyte number presented a strong association with PEC activation ( Figure 6G ).
While glomeruli from Pod-TSC1 +/+ mice showed a strong association between podocyte number and glomerular volume, there was no correlation between both parameters in glomeruli from Pod-TSC1 -/mice ( Figure 6H ), suggesting dramatic podocyte loss across the entire glomerular size spectrum. As glomeruli underwent hypertrophy in Pod-TSC1 -/mice, podocyte hypertrophy was more pronounced ( Figure 6I ). Furthermore, as podocyte loss progressed in Pod-TSC1 -/mice, podocyte hypertrophy was exacerbated ( Figure 6J) . Changes in glomerular size (Supplemental Figure 5C ) or podocyte volume (Supplemental Figure 5D ) did not correlate with PEC activation. Together, these findings indicate that exaggerated podocyte hypertrophy functions as an indirect driver of PEC activation by facilitating accelerated and progressive podocyte loss.
Pharmacological mTOR inhibition impairs mouse podocyte hypertrophy. Next, we explored the consequences of pharmacological mTOR inhibition during active podocyte loss. RAD001 (mTORC1 inhibitor) and INK128 (global mTOR inhibitor) were administered daily starting 24 hours before DT injection and throughout 3 weeks of follow-up in Pod Cre iDTR mice injected with a low dose of DT ( Figure 7A ). Successful mTORC1 inhibition was confirmed via indirect immunofluorescence and confocal microscopy using p-rp-S6 ( Figure 7B ). Systemic administration of mTOR inhibitors was directly associated with exacerbated and persistent albuminuria, reaching levels observed in mice injected with high-dose DT ( Figure 7C ). Three weeks after DT injection, glomerulosclerotic lesions were identified only in mice with mTOR inhibition ( Figure 7D ) and were observed with a similar frequency as in mice with high-dose DT ( Figure 7E ). Pharmacological mTOR inhibition in noninjected Pod Cre iDTR mice did not lead to albuminuria (Supplemental Figure 6A ), podocyte loss (Supplemental Figure 6B ), PEC activation (Supplemental Figure 6C ), or glomerulosclerosis (Supplemental Figure 6D) . In contrast, Pod Cre iDTR mice injected with a low dose of DT during ongoing mTOR inhibition developed strong PEC activation ( Figure 7F ). Unlike all of our previous models, podocyte loss ( Figure 7G ) was not matched by compensatory podocyte hypertrophy ( Figure 7H ). Given that pharmacological mTOR inhibition is not cell specific, we used in vitro systems in order to test the direct effect of mTOR inhibitors on podocytes and PECs. First, we induced podocyte hypertrophy via serum starvation/stimulation (Supplemental Figure 7A ). We were able to clearly inhibit the hypertrophic response of podocytes in vitro using both RAD001 and INK128 (Supplemental Figure 7B ). Then, we tested PEC migration as a functional readout of PEC activation in vitro. Under normal in vitro conditions, PECs are under a state of mild activation and are able to dynamically migrate. The addition of RAD001 or INK128 did not affect their migration speed (Supplemental Figure 7C ) or transcriptional regulation of proactivation factors CD44 or COL4 (Supplemental Figure 7D) . These results confirm a physiological role of mTOR-mediated podocyte hypertrophy in the regulation of glomerular functional integrity during periods of acute podocyte loss.
Identifying the limits of podocyte loss and hypertrophy in mice and humans. Finally, we aggregated all our morphometric data and summarized it in Figure 8 . Percentages of podocyte depletion and hypertrophy (experimental group vs. control as normalization strategy) were calculated ( Figure 8, A and B ). Using both models and combined data from mice and humans, we identified that the apparent limit of podocyte depletion lies below 24% of podocyte depletion, after which PEC activation and glomerulosclerosis were consistently identified, despite dramatic increases in podocyte size ( Figure 8C ). The best example of this limit can be observed in our hyperglycemic mice, as injection of a small dose of DT was sufficient to achieve the depletion percentage necessary to develop glomerulosclerotic lesions.
Discussion
The mTORC1 acts as a central regulator of cell size (17, 31) . mTOR signaling is essential during kidney development and for kidney growth during physiological body growth (18) . In contrast, hyperactivity of the mTOR pathway in podocytes leads to pathological changes associated with diabetic nephropathy (19) and crescentic nephritis (20) . While inhibition of mTOR signaling has proven to be an effective therapeutic approach (16) , the clinical use of mTOR inhibitors has been associated with proteinuria and de novo FSGS (21) (22) (23) (24) (25) (26) (27) . For this reason, the use of mTOR inhibitors in glomerular diseases remains controversial.
In a recent publication, Zschiedrich et al. (28) blocked mTORC1 signaling in podocytes and performed subtotal nephrectomy, a model of glomerular hypertrophy, which showcased the protective role of mTORC1 as a physiological response. Nishizono et al. (29) also showed that modulation of the mTORC1 pathway in podocytes impaired their capacity to adapt to exacerbated glomerular hypertrophy, thereby leading to FSGS. Our findings clearly agree with the protective role of podocyte hypertrophy proposed by both groups and provide a potentially new perspective based on the importance of mTOR-mediated podocyte hypertrophy for functional glomerular integrity following podocyte loss, independent of glomerular size. We hypothesize that patients experience cyclic episodes of podocyte loss during glomerular stress, mostly in association with known CKD risk factors such as aging, hypertension, and obesity (7) . Therefore, understanding the potential consequences of an intervention that actively blocks this signaling pathway has direct clinical relevance.
Our data show that inhibition of mTOR signaling during the induction of podocyte loss leads to PEC activation and glomerulosclerosis, as the protective hypertrophic response of podocytes is significantly impaired. With this information, our current study expands on the therapeutic recommendations made by Zschiedrich et al. (28) , suggesting that mTOR inhibition should be avoided in patients with immediate requirements for mTOR-mediated podocyte hypertrophy (i.e., patients with active podocyte loss). This raises an important issue: how can physicians determine if active podocyte loss is taking place in their patients? While a definitive answer is not available, an interesting alternative may be found in the analysis of urinary markers of podocyte loss (32) (33) (34) . However, we believe there is a growing need for the development of noninvasive methods to assess podocyte loss.
In a recent report (35) , we showed in human autopsy tissue that, even when large adult glomeruli contained more podocytes than small glomeruli from young children, the extent of glomerular hypertrophy from childhood to adulthood resulted in a marked reduction in podocyte density. Our current analyses of human tissue add to our previous findings by showing that podocyte hypertrophy is present in subjects without kidney disease during normal somatic growth, which in turn drives glomerular hypertrophy to compensate for increasing metabolic demands in adulthood (36, 37) , as previously described by Kikuchi et al. (38) using different quantification approaches and experimental designs. For these reasons, the role of mTOR-mediated podocyte hypertrophy should be carefully examined in periods of rapid body growth (puberty, pregnancy) or expected compensatory glomerular hypertrophy/hyperfiltration.
Our current data also show that reductions in podocyte density and increases in podocyte size are both exacerbated in human FSGS, suggesting that podocyte hypertrophy was not able to match the loss of podocytes and preserve glomerular integrity. Previous work by Hodgin et al. (39) showed that age-related reductions in podocyte density lead to podocyte hypertrophy, which may place podocytes under stress and eventually facilitate the development of glomerulosclerosis. Furthermore, Fukuda et al. (40) reported that angiotensin-2mediated progressive podocyte loss led to destabilization of glomeruli with severe podocyte depletion. Both studies elegantly highlight that podocyte hypertrophy has a limit when subjected to chronic or significant stress. We explored the limits of podocyte hypertrophy using 2 different approaches: (a) a 1-hit model as we induced selective podocyte loss beyond the compensatory limit of podocyte hypertrophy, and (b) a 2-hit model as we generated an adverse environment (i.e., hyperglycemia) and induced subsequent selective podocyte loss that, under normal conditions, is tolerated. The results in both cases were identical, demonstrating exacerbated podocyte hypertrophy combined with PEC activation and glomerulosclerosis, raising an important question: why is podocyte hypertrophy unable to preserve functional glomerular integrity in such settings?
Unfortunately, the answer to this question lies beyond the scope of our study. It has been proposed that podocyte loss leaves denuded areas of glomerular basement membrane, allowing molecules that would normally mainly remain in capillaries to more readily cross into the urinary space, including albumin, and growth factors (such as PDGF). Hakroush et al. (41) has shown that severe podocyte depletion leads to rapid PEC activation and glomerulosclerotic lesions. We postulate that PECs are able to quickly identify the "leakiness" of the glomerular filtration barrier (42, 43) , which will serve as a trigger for PEC activation.
Interestingly, a recent publication shows that blocking tetraspanin CD9 signaling in PECs is sufficient to prevent glomerulosclerosis (44) , which may be directly related to the capacity of PECs to sense signals from neighboring cells (e.g., endothelial cells or podocytes). Thus, there is growing interest in the field of PEC biology as they emerge as potential therapeutic targets.
PECs have also gained attention as potential sources of additional podocytes in the postnatal period (14) . Recent publications have shown that podocyte regeneration may be possible in specific scenarios (45) (46) (47) (48) (49) (50) (51) , but other publications have ruled this out (10, 52) . Conflicting evidence may highlight differences in glomerular injury models, mouse backgrounds, adequacy of wash-out periods, transgene leakiness, and quantification methods, among other factors. In the current study, we have performed multiple experiments where the main compensatory response is podocyte hypertrophy in the absence of detectable podocyte regeneration. While it is possible that small (negligible) postnatal podocyte gain may be missed in our studies, podocyte hypertrophy appears to be a much more efficient compensatory response in order to cope with podocyte depletion.
It is also worth noting that podocyte hypertrophy has a physiological limit. Wiggins et al. (53) proposed stages for podocyte hypertrophy and suggested that there is a limit for podocyte growth that, when reached, would lead to podocyte detachment, creating a vicious cycle of podocyte loss and glomerulosclerosis. Building on this concept, Zschiedrich et al. (28) proposed a therapeutic window for mTOR inhibition, as the compensatory function of podocyte hypertrophy is exhausted and exacerbated podocyte hypertrophy compromises podocyte integrity, leading to podocyte loss. Our findings in Pod-TSC1 -/mice are in agreement with both of these studies, as we quantified excessive levels of podocyte hypertrophy induced by hyperactivation of mTORC1. Importantly, the development of FSGS in Pod-TSC1 -/mice directly correlated with glomerular hypertrophy and accelerated podocyte loss, leading to PEC activation. Together, mTORC1 hyperactivation in podocytes remains an attractive therapeutic target. We propose that future studies should carefully determine surrogate markers for a safe therapeutic window, aiming to control exaggerated podocyte hypertrophy without interfering with its compensatory role.
In conclusion, this study shows a critical protective role of mTOR-mediated podocyte hypertrophy after podocyte loss in the absence of detectable podocyte regeneration. Our findings suggest that podocyte hypertrophy regulates glomerular integrity until a threshold of podocyte depletion is reached, after which even exacerbated podocyte hypertrophy is unable to prevent PEC activation and glomerulosclerosis. Furthermore, excessive mTOR-mediated podocyte hypertrophy enhances podocyte loss and perpetuates a cycle of podocyte depletion and glomerulosclerosis.
